This study is for patients with Multiple Myeloma (MM), a type of blood cancer. After a special treatment called autologous stem cell transplant (taking your own healthy stem cells), patients will receive either elranatamab or lenalidomide. Elranatamab is a special protein, called a bispecific antibody, that helps your immune cells attack cancer cells. Lenalidomide is a pill you take at home. The study will last about five years.

• Study length is approximately five years.
• Participants receive treatment either as an injection at the clinic or oral medication at home.
• Participants must meet specific health criteria to join.

To join, you need to have had a transplant for MM and meet other health requirements. You can't join if you have certain other health problems like some infections or other cancers. It's important to consider if you're willing to commit to a long study and meet all the health checks before enrolling.